All companies
Cooper Companies logo

What smart money is saying about Cooper CompaniesUnited States flag

COO · Healthcare · Medical - Instruments & Supplies · Market cap $13.20B

6 funds in our archive have pitched Cooper Companies — most recently Harris Associates Global All Cap Strategy in June 2026.

Company profile

The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.

Get an email when a fund writes about it

Summarize with Warren AI
1
Reported positions
1
Bought
0
Sold
6
Letters

Position history

Between Q1 2025 and Q2 2026, 1 fund letter reported a position in Cooper Companies1 opened or added to the position.

Fund letters reporting a position in Cooper Companies, by quarter
QuarterLettersBoughtSoldTheses
Q2 20261101
Q4 20250003
Q3 20250001
Q1 20250001

Fund activity · 1 position · 1 move

  • New positionHarris Associates Global All Cap Strategy
    June 2026
    We initiated the following position(s) during the pe- riod:
    Read the letterCooper Companies

Fund coverage · 6 theses

  • Harris Associates Global All Cap Strategy
    June 2026

    Cooper Companies benefits from an oligopolistic contact lens market, market share gains, and an attractive valuation.

    Read the full thesis
  • The London Company Mid Cap
    December 2025

    Cooper Companies operates high-quality vision and women's health businesses with durable advantages and margin expansion catalysts alongside attractive valuation and activist-driven improvements.

    Read the full thesis
  • Diamond Hill Large Cap Fund
    December 2025

    The Cooper Companies is a global leader in contact lenses and women's health poised for long-term growth and modest share gains despite near-term headwinds.

    Read the full thesis
  • Davenport
    December 2025

    The Cooper Companies, Inc. is a leading contact lens maker with annuity-like demand, strong R&D, premium products, attractive entry valuation, insider buying, and potential value unlocks.

    Read the full thesis
  • Diamond Hill Long Short Fund
    September 2025

    Cooper Companies is a medical devices company with strong growth potential in contact lenses and women's health, supported by recent investments and favorable market trends.

    Read the full thesis
  • Pender US Small Mid
    March 2025

    Cooper Companies is a resilient global medical device leader in contact lenses and women's healthcare, benefiting from strong market positions and growth potential in both sectors.

    Read the full thesis

Read every full thesis on Cooper Companies

Unlock all 6 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.

View plans
Share this ledger